Article

Pediatric dosage approved for rare brain tumor

Author(s):

On Aug. 29, the FDA approved Afinitor Disperz (everolimus tablets for oral suspension), making it the first pediatric dosage approved for a pediatric tumor. While Afinitor has previously been available for patients 3 years or older, this new dosage form is to treat patients one year and older with tuberous sclerosis complex (TSC) who have a rare brain tumor, subependymal giant cell astrocytoma (SEGA), that can't be treated surgically. TSC is a genetic disorder that causes noncancerous tumors to form in various organs, and even though the tumors are noncancerous, they can still cause complications. SEGA tumors are generally slow-growing and form in 1 out of 10 individuals with TSC. SEGA is also more likely to affect children and young adults under 21. This dosage form is available in smaller amounts than the adult dosage and can dissolve in a small amount of water, making it easier to swallow. Side effects include mouth ulcers and respiratory tract infections. For more information on the approval visit the FDA site.For more information on TSC and SEGA, visit tsalliance.org.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content